EDAP TMS $28 million follow-on offering
We advised the underwriters on the equity offering

Davis Polk advised the underwriters in connection with the $28 million public offering by EDAP TMS S.A. of 4,150,000 American depositary shares, each representing one ordinary share. The ordinary shares, represented by ADSs, are listed on the Nasdaq Global Market under the symbol “EDAP.”

Based in France, EDAP develops and markets robotic High Intensity Focused Ultrasound devices, advanced choices for use in the treatment of localized prostate cancer. It also produces and commercializes medical equipment for the treatment of urinary tract stones using Extracorporeal ShockWave Lithotripsy, and distributes other types of urology devices in certain countries.

The Davis Polk corporate team included partner Alan F. Denenberg and associate Ganiatu Afolabi. Partner Jacques Naquet-Radiguet and associates Stéphane Daniel and Johann Jabes provided French law advice. Partner Frank J. Azzopardi and associate Hilary Smith provided intellectual property advice. Counsel Ethan R. Goldman and associate Ben Levenback provided tax advice. Members of the Davis Polk team are based in the Northern California, New York and Paris offices.